Related Experiment Video
Updated: Jun 28, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia
Noël J M Raynal1, Michel Charbonneau, Louise F Momparler
1INRS-Institut Armand-Frappier, Université du Québec, Laval, Quebec H7V 1B7, Canada.
Abstract:
5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation, is an effective agent for the treatment of leukemia. The aim of this study was to investigate the antileukemic activity of this epigenetic agent in combination with genistein, a nontoxic isoflavone with chemopreventive activity. The combined treatment produced a synergistic loss of clonogenicity in human myeloid (HL-60) and lymphoid (MOLT-3) leukemic cell lines. Genistein alone showed a significant antileukemic activity against murine 5-AZA-CdR-resistant cells, and this effect was enhanced when used in combination with 5-AZA-CdR. The combined treatment also produced a synergistic increase in life span of mice with L1210 leukemia. These results suggest that genistein may have the potential to increase the clinical efficacy of 5-AZA-CdR for the treatment of leukemia.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
